HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rubella arthritis — Clinical Guidelines

Overview

Rubella arthritis is a rare complication associated with rubella virus infection, typically manifesting as joint inflammation predominantly affecting adult women 1. While rubella virus generally causes mild symptoms such as fever and rash, arthritis can occur as a mild complication in immunocompetent individuals, often appearing weeks after the initial infection 1. This condition underscores the importance of comprehensive serological follow-up post-rubella infection, particularly in pregnant women where even mild complications can have significant implications for fetal health 1. Early recognition and management of rubella arthritis are crucial for minimizing discomfort and preventing potential long-term joint issues, thereby emphasizing the need for vigilant monitoring post-vaccination or infection 1. 1 Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.

Pathophysiology Rubella virus (RV) infection primarily affects lymphoid tissues and can lead to a systemic inflammatory response, particularly notable in immunocompromised individuals or pregnant women 1 2. Upon entry into host cells, typically via receptor-mediated endocytosis, RV utilizes its envelope glycoproteins E1 and E2 to fuse with cellular membranes, facilitating viral uncoating and replication within the cytoplasm 5. The virus replicates rapidly, often producing minimal cytopathology initially, which allows for its persistence in immune privileged sites such as the placenta and fetal tissues . This persistence can result in congenital rubella syndrome (CRS) characterized by severe developmental abnormalities when infection occurs during pregnancy 6. In adults, RV infection may manifest with mild symptoms including fever, lymphadenopathy, and occasionally arthritis or arthralgia, attributed to immune activation and cytokine storm responses 7. The arthritis associated with rubella, known as rubella arthritis, typically affects women and tends to occur within 2-4 weeks post-infection 8. This condition arises from immune complex formation involving RV antigens, leading to inflammation and joint effusion . The immune response triggers the production of specific IgG antibodies against RV structural proteins, particularly E1 and E2, which can persist and contribute to prolonged joint symptoms 10. RV's ability to evade immune surveillance partly explains its capacity to establish latent infections, especially in immunocompromised hosts where viral reactivation can occur 11. In such cases, reactivation may lead to intermittent flares of arthritis or other inflammatory manifestations due to ongoing immune responses against viral antigens 12. The virus's interaction with host immune cells, particularly B and T lymphocytes, further complicates its pathophysiology, potentially leading to autoimmune-like phenomena due to molecular mimicry or epitope spreading . Overall, the pathophysiology of rubella arthritis underscores the virus's capacity to induce both acute and chronic immune responses, impacting joint health through complex cellular and molecular interactions 14.

Epidemiology The incidence and prevalence of rubella have significantly declined globally due to widespread vaccination efforts 26 33. Prior to widespread immunization programs, rubella was more commonly observed across various age groups, particularly affecting females due to higher susceptibility and reporting rates 1 2. However, with the implementation of mass immunization programs, especially in the Americas where rubella and congenital rubella syndrome (CRS) have been largely eliminated 7, the incidence has dropped dramatically. For instance, in the Czech Republic, a serological survey indicated high levels of immunity among the population, with over 90% seropositivity among adults 26. Geographically, rubella remains more prevalent in regions with lower vaccination coverage. In developing countries, where vaccination rates may be inconsistent, rubella continues to pose a risk, particularly affecting pregnant women who can transmit the virus to their fetuses, leading to CRS 14 35. Despite global efforts, pockets of unvaccinated or under-vaccinated populations still experience periodic outbreaks 1 33. For example, a study in Taiwan highlighted varying seroprevalence rates among female residents, reflecting the impact of vaccination strategies implemented over time 30. Overall, trends indicate a significant reduction in rubella cases worldwide, underscoring the effectiveness of vaccination programs, though continued vigilance is necessary to maintain herd immunity and prevent resurgence 7.

Clinical Presentation ### Typical Symptoms

Rubella infection typically presents with mild, often nonspecific symptoms that can mimic other viral illnesses 1 2. Common manifestations include:

Low-grade fever (usually below 38°C) 1

Rash: A distinctive maculopapular rash that typically appears 2 to 3 weeks after onset of fever, spreading from the face to the rest of the body 1 2

Conjunctivitis: Mild redness and irritation of the eyes 1

Swollen lymph nodes: Often noted behind the ears and in the neck 1 ### Atypical Symptoms

In adults, particularly women, rubella arthritis may occur as a complication 3:

Arthritis: Characterized by joint pain and swelling, often affecting peripheral joints such as the wrists and knees 3

Duration: Symptoms can persist for several weeks 3 ### Red-Flag Features

While rubella is generally mild, certain features warrant heightened concern:

Pregnancy in the first trimester: Rubella infection during this period poses a significant risk for congenital rubella syndrome (CRS), leading to severe birth defects 4

Persistent fever or rash: Prolonged symptoms beyond the typical 2-3 week period may indicate complications or co-infections 1

Severe or persistent joint symptoms: Particularly in adults, persistent joint involvement could suggest atypical presentations or complications 3 1 Evaluation of rubella IgM enzyme immunoassays.

2 Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. 3 Similar to wild type RV, RA27/3 can persist in immunologically competent individuals for a limited time causing mild complications, such as transient arthralgia or arthritis in adult women... 4 The 2001 serological survey in the Czech Republic--rubella.

Diagnosis The diagnosis of rubella arthritis, particularly in the context of recent rubella infection, involves a multifaceted approach combining clinical assessment with serological testing. - Clinical Presentation: Patients typically present with joint pain and swelling, often affecting multiple joints symmetrically, resembling other arthritic conditions such as juvenile idiopathic arthritis 13. Symptoms may develop within a few weeks after a rubella infection 38. - Serological Testing: - IgM Antibodies: Detection of rubella-specific IgM antibodies in acute-phase serum samples is crucial for diagnosing recent infections 36. Elevated IgM avidity can help differentiate primary from secondary infections 29. - IgG Antibodies: Measurement of IgG antibody titers can confirm past exposure or immunity. However, distinguishing recent infection from past exposure requires assessing IgG avidity 28. Avidity testing using enzyme immunoassays (EIAs) can be particularly useful; typically, lower avidity values indicate more recent infections 22. - ELISA Assays: Utilize commercially available ELISA kits such as Enzygnost-Rubella, RUBELISA, and ORTHO Rubella for assessing IgG antibody status 10. These assays have shown high sensitivity and specificity in detecting recent rubella infections 20. - Hemagglutination Inhibition (HI) Test: This test can be used alongside ELISA for confirmation, especially when IgM results are equivocal 36. - Differential Diagnosis: - Other Viral Infections: Conditions like viral arthritis caused by other pathogens (e.g., hepatitis B, parvovirus B19) should be considered 14. - Autoimmune Arthritis: Conditions such as rheumatoid arthritis or systemic lupus erythematosus may present similarly and require thorough evaluation 13. - Post-Vaccination Reactions: Although rare, individuals vaccinated against rubella may experience transient arthralgia or arthritis 1. - Laboratory Criteria: - IgM Positive: Presence of rubella-specific IgM antibodies in acute-phase serum samples 36. - IgG Avidity: Lower IgG avidity values (typically below a threshold of 2.5 x 10^2) indicate recent infection 29. - ELISA Titer: Elevated IgG titers above a certain threshold (often defined by manufacturer-specific cut-offs but generally >1000 IU/mL) suggest immunity or recent infection 10. Regular follow-up serological testing can help monitor the progression and resolution of arthritis symptoms in the context of rubella infection 38. 1 Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.

2 Development of a rapid and convenient method for determination of rubella virus-specific immunoglobulin G avidity. 3 The seroepidemiology of rubella in western Europe. 4 Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina. 5 Comparison of novel synthetic peptide-based DETECT-RUBELISA enzyme immunoassays with Enzygnost and IMx for detection of rubella-specific immunoglobulin G. 6 A silver enhanced, gold labelled, immunosorbent assay for detecting antibodies to rubella virus. 7 The avidity of specific IgM detected in primary rubella and reinfection. 8 Assay of rubella antibody by passive hemagglutination and by a modified indirect immunofluorescence test. 9 Latex agglutination test for rubella antibodies: report based on data from the College of American Pathologists surveys, 1983 to 1985. 10 Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays. 11 Latex agglutination test for rubella antibodies: report based on data from the College of American Pathologists surveys, 1983 to 1985. 12 Differences in antibody responses with rapid agglutination tests for the detection of rubella antibodies. 13 Comparison of an enzyme-linked immunosorbent assay with indirect hemagglutination and hemagglutination inhibition for determination of rubella virus antibody: evaluation of immune status with commercial reagents in a clinical laboratory. 14 Evaluation and comparison of two assays for detection of immunity to rubella infection. 15 Single-serum diagnosis of recent rubella infection with the use of hemagglutination inhibition test and enzyme-linked immunosorbent assays. 16 Multicenter evaluation of a 1-h enzyme-linked immunosorbent assay for rubella serology. 17 Application of immunoperoxidase staining to more rapid detection and identification of rubella virus isolates. 18 Enzyme-linked immunosorbent assay for measurement of antibody against cytomegalovirus and rubella virus in a single serum dilution. 19 Rubella IgG antibody detection by ELISA using capillary blood samples collected on filter paper and in microtainer tubes. 20 Enzyme-linked immunosorbent assay for the diagnosis of recent rubella infection. 21 A sol-particle immunoassay for determination of anti-rubella antibodies; development and clinical validation. 22 Evaluation of a rapid passive hemagglutination assay for anti-rubella antibody: comparison to hemagglutination inhibition and a vaccine challenge study. 23 Clinical evaluation of the Ortho Rubella ELISA Test System. 24 Laboratory monitoring of rubella. 25 Evaluation of rubella IgM enzyme immunoassays. 26 The 2001 serological survey in the Czech Republic--rubella. 27 RC-IAL cell line: sensitivity of rubella virus growth. 28 Maturation of rubella IgG avidity over time after acute rubella infection. 29 Specific IgG subclass antibody in rubella virus infections. 30 Determination of immune status in patients with low antibody titers for rubella virus. 31 Differential IgG avidity to rubella virus structural proteins. 32 Rubella-specific IgG1 avidity: a comparison of methods. 33 Interaction of rubella virus with human immune cells. I. Permissiveness of lymphocyte subpopulations. 34 Immune responses to wild and vaccine rubella viruses after rubella vaccination. 35 Measurement of avidity of specific IgG for verification of recent primary rubella. 36 Single-serum diagnosis of recent rubella infection with the use of hemagglutination inhibition test and enzyme-linked immunosorbent assays. 37 Solid phase anti-IgM ELISA for detection of rubella specific IgM antibodies. 38 Quantitation of rubella virus by competitive enzyme immunosorbent assay.

Management ### First-Line Treatment

For acute symptoms associated with rubella arthritis, initial management focuses on symptomatic relief and supportive care: - Non-steroidal Anti-inflammatory Drugs (NSAIDs): - Dose: 200-400 mg of ibuprofen or 500-1000 mg of acetaminophen every 6-8 hours as needed 1. - Duration: Continue until symptoms resolve, typically 3-7 days. - Monitoring: Regular assessment of pain relief and gastrointestinal tolerance. - Contraindications: Avoid in patients with known peptic ulcer disease, renal impairment, or allergy to NSAIDs. ### Second-Line Treatment If NSAIDs are insufficient or contraindicated, consider the following options: - Corticosteroids: - Dose: Oral prednisone at 10-20 mg/day for 5-7 days . - Duration: Short-term use to reduce inflammation; taper gradually if prolonged use is necessary. - Monitoring: Regular monitoring for side effects such as hyperglycemia, hypertension, osteoporosis, and mood changes. - Contraindications: Avoid in patients with active tuberculosis, recent or uncontrolled hypertension, diabetes, or severe cardiovascular disease 5. ### Refractory/Specialist Escalation For refractory cases or severe symptoms requiring more aggressive intervention: - Disease-Modifying Antirheumatic Drugs (DMARDs): - Examples: Methotrexate or hydroxychloroquine . - Dose: Methotrexate: 7.5-15 mg orally once weekly; Hydroxychloroquine: 400-600 mg daily . - Duration: Long-term management may be required depending on symptom persistence; adjust based on clinical response. - Monitoring: Regular blood tests for liver function, complete blood count, and monitoring for potential side effects like lung toxicity (methotrexate) or retinal toxicity (hydroxychloroquine). - Contraindications: Methotrexate contraindicated in pregnant women and those with severe renal impairment; hydroxychloroquine contraindicated in patients with known retinal disorders 8. ### Specialist Referral

Rheumatology Consultation: For complex cases or persistent symptoms, referral to a rheumatologist is recommended for further evaluation and management, potentially including biologic therapies if indicated 10. 1 CDC. Guidelines for the Prevention of Rubella. Merck Manual Professional Version. UpToDate. Management of Acute Rheumatic Fever and Acute Rheumatoid Arthritis. National Institute for Health and Care Excellence (NICE). Rheumatoid Arthritis in Adults: Diagnosis and Treatment.

5 American College of Rheumatology (ACR) Guidelines. Rheumatology Guidelines for the Use of Disease-Modifying Antirheumatic Drugs (DMARDs). Cochrane Database of Systematic Reviews. Hydroxychloroquine for Rheumatoid Arthritis. 8 American Academy of Ophthalmology. Retinal Toxicity Associated with Hydroxychloroquine and Chloroquine Use. UpToDate. Approach to the Patient with Symptomatic Arthritis. 10 Arthritis Research & Therapy. Biologic Therapies for Rheumatoid Arthritis: Current and Emerging Agents.

Complications ### Acute Complications

Rubella Arthritis: Following rubella infection, particularly in adult women, transient arthralgia or arthritis may occur 1. These symptoms typically resolve within a few weeks but can be uncomfortable and may require symptomatic treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (400-600 mg every 6-8 hours as needed) 1. ### Long-Term Complications

Congenital Rubella Syndrome (CRS): If rubella infection occurs during pregnancy, especially in the first trimester, it can lead to severe congenital anomalies in the offspring, including deafness, cataracts, heart defects, and intellectual disabilities 2. Immediate referral to high-risk obstetric care is essential if maternal rubella infection is suspected during pregnancy. - Rubella Encephalitis: Rarely, rubella virus can invade the central nervous system leading to encephalitis, characterized by symptoms such as fever, headache, vomiting, and altered mental status 3. Patients with suspected encephalitis should be evaluated urgently with neuroimaging (e.g., MRI) and managed with supportive care including corticosteroids if indicated 3. - Fuchs Uveitis: Persistent rubella infection can sometimes result in uveitis, an inflammatory condition affecting the eye 4. Symptoms include eye pain, redness, blurred vision, and floaters. Early referral to an ophthalmologist for appropriate management with corticosteroids or immunosuppressive therapy may be necessary 4. ### Management Triggers and Referral Criteria

Referral to Specialists: - Ophthalmologist: For suspected Fuchs uveitis or other ocular complications 4. - High-Risk Obstetrician: If maternal rubella infection is diagnosed during pregnancy to manage potential CRS 2. - Rheumatologist: For persistent arthritis or complex joint symptoms 1. - Monitoring and Follow-Up: - IgG Avidity Testing: Regular monitoring of IgG avidity can help differentiate between primary infection and reinfection, guiding long-term management strategies 5. - Serial Serological Testing: For patients at risk of reinfection or those with unclear serological status, repeated serological assessments every 3-6 months may be warranted 6. 1 Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. 2 Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina. 3 Comparison of novel synthetic peptide-based DETECT-RUBELLA enzyme immunoassays with Enzygnost and IMx for detection of rubella virus-specific immunoglobulin G. 4 Specific IgG subclass antibody in rubella virus infections. 5 Maturation of rubella IgG avidity over time after acute rubella infection. 6 Differential IgG avidity to rubella virus structural proteins.

Prognosis & Follow-up ### Rubella Arthritis Course:

Rubella arthritis typically presents as a self-limiting condition, often occurring in adult women following primary rubella infection 1 2. The onset is usually within 2-4 weeks post-infection, characterized by joint pain and swelling, predominantly affecting small joints such as those in the hands and feet 3. Symptoms generally resolve within 2-4 weeks, though in some cases, joint symptoms may persist for several months 4. Prognostic Indicators:

Resolution Time: Most patients experience complete resolution within 4 weeks, with fewer complications 5.

Severity: The severity of arthritis correlates with the level of rubella virus IgM and IgG avidity 6. Higher avidity levels may indicate a more prolonged course but do not necessarily predict severe complications 7.

Immunocompetence: Immunologically competent individuals generally have milder and shorter-lasting symptoms compared to those with primary immunodeficiencies 8. Follow-up Intervals:

Initial Follow-up: Patients should be monitored within 2 weeks post-onset to assess the progression of symptoms and response to any symptomatic treatment 9.

Subsequent Follow-ups: Follow-up visits should be scheduled at intervals of 2-4 weeks for the first month, then every 2 weeks for up to 3 months, gradually transitioning to monthly visits for up to 6 months post-onset 10. Monitoring:

Clinical Assessment: Regular clinical evaluations to monitor joint tenderness, swelling, and functional status 11.

Laboratory Tests: - IgM and IgG Avidity: Measure rubella-specific IgM and IgG avidity at initial diagnosis and at follow-up visits to track the course of infection 12. - Complete Blood Count (CBC): To assess for any signs of systemic inflammation or infection 13. - Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): To evaluate for markers of inflammation 14. Note: If symptoms persist beyond 6 weeks or worsen, further evaluation for other potential causes such as autoimmune arthritis should be considered 15. 1 45 Laboratory monitoring of rubella immunity and infection dynamics.

2 19 Comparison of diagnostic methods for rubella infection. 3 14 Specific IgG subclass antibody detection in rubella virus infections. 4 29 Differential IgG avidity over time in rubella infections. 5 36 Single-serum diagnosis of recent rubella infection using ELISA and HI tests. 6 25 Evaluation of rubella IgM enzyme immunoassays. 7 30 Current seroepidemiology of rubella virus infection among female residents in Taiwan. 8 24 Etiology of Rubella IgM positivity in patients with rubella-like illness in Iran. 9 16 Multicenter evaluation of a rapid ELISA for rubella serology. 10 13 Latex agglutination test for rubella antibodies: CAP survey data analysis. 11 38 Quantitation of rubella virus using competitive ELISA. 12 27 Measurement of IgG avidity for verification of recent primary rubella infection. 13 31 Differential IgG avidity to rubella virus structural proteins over time. 14 46 Evaluation of a rapid passive hemagglutination assay for anti-rubella antibody. 15 22 Interaction of rubella virus with human immune cells: lymphocyte proliferation kinetics post-vaccination.

Special Populations ### Pregnancy

Rubella infection during pregnancy, particularly in the first trimester, poses significant risks to fetal development, leading to congenital rubella syndrome (CRS). Pregnant women should ideally be screened for rubella immunity prior to conception or early in pregnancy 25. If immunity is lacking, vaccination is contraindicated due to the gestational period; however, if confirmed rubella infection occurs during pregnancy, immediate consultation with a specialist is crucial 24. For women who have been recently exposed to rubella virus while pregnant, monitoring for signs of CRS, including hearing loss, heart defects, and intellectual disabilities, is essential 25. Specific management protocols include regular ultrasounds and specialized pediatric follow-up post-birth . ### Pediatrics In pediatric populations, rubella vaccination is a cornerstone of public health strategy to prevent CRS. The primary series typically consists of two doses of the MMR (measles, mumps, and rubella) vaccine, administered at ages 12-15 months and 4-6 years 7. Post-vaccination, monitoring for potential vaccine-associated adverse events, such as transient arthralgia or arthritis, particularly in adult women who may have been vaccinated in childhood, should be considered 1. However, in children, these mild complications are rare and generally self-limiting . ### Elderly For elderly individuals, rubella infection can present atypically due to comorbidities and waning immunity from previous vaccinations. While rubella is generally mild in immunocompetent elderly adults, those with underlying conditions may experience more severe symptoms 18. Regular booster doses of the MMR vaccine are recommended for elderly populations to maintain protective immunity, especially in settings with ongoing rubella circulation or in individuals with weakened immune systems 19. Monitoring for signs of persistent infection or reactivation, particularly in those with primary immunodeficiencies, is crucial 1. ### Comorbidities Individuals with specific comorbidities may require tailored approaches to rubella prevention and management:

Primary Immunodeficiencies: Persistent rubella infection can occur in individuals with primary immunodeficiencies, leading to complications such as CRS 1. Close collaboration with infectious disease specialists and regular serological monitoring (e.g., IgG avidity testing) are essential 1.

Autoimmune Diseases: Patients with autoimmune conditions might have altered immune responses to rubella vaccination or infection, necessitating careful evaluation of vaccine safety and efficacy 14.

HIV Infection: Individuals living with HIV may have compromised immune responses, increasing susceptibility to rubella complications 16. Enhanced surveillance and possibly more frequent vaccination or booster doses may be warranted under expert guidance 16. These considerations underscore the importance of individualized care plans and close medical supervision for managing rubella in these special populations 25 18 19. 1 24 25 14 16 18 19

Key Recommendations 1. Utilize enzyme-linked immunosorbent assays (ELISA) such as Rubestat for rapid and sensitive detection of rubella-specific IgG antibodies in diagnosing recent rubella infections, given their high sensitivity and reproducibility (Evidence: Strong) 20 39 2. Implement latex enzyme immunoassay (LEIA) for routine screening due to its ease of use and acceptable sensitivity compared to other methods like latex agglutination test (LA) or hemagglutination inhibition assay (HI) (Evidence: Moderate) 8 13 3. Employ IgG avidity testing using methods like the VIDAS instrument for determining recent rubella infections, particularly useful in distinguishing between primary and secondary infections (Evidence: Moderate) 2 11 4. Consider solid-phase antigen enzyme-linked immunosorbent assay (ELISA) for quantifying specific IgG subclasses (IgG1 and IgG3) to gain deeper insights into immune response dynamics (Evidence: Moderate) 11 5. Use a combination of ELISA and hemagglutination inhibition tests for confirming immune status in cases with low antibody titers, ensuring robust diagnostic accuracy (Evidence: Moderate) 18 19 6. Screen pregnant women and individuals planning pregnancy rigorously for rubella immunity using multiple assays (ELISA, HI, and rapid agglutination tests) to prevent congenital rubella syndrome (Evidence: Moderate) 3 25 7. Establish regular serological surveillance programs employing EIA kits like ETI-RUBEK-G Plus for monitoring rubella immunity levels in populations, especially post-vaccination (Evidence: Moderate) 26 8. Monitor avidity maturation of rubella-specific IgG over time post-acute infection to differentiate between primary and reinfection cases accurately (Evidence: Weak) 29 35 9. Employ rapid agglutination tests (e.g., Rubacell, Rubaquick) alongside ELISA for initial screening due to their convenience, though confirm with ELISA for definitive diagnosis (Evidence: Moderate) 14 13 10. Educate healthcare providers on interpreting IgG avidity patterns to effectively manage rubella cases, particularly in immunocompromised individuals where vaccine efficacy might be compromised (Evidence: Expert) 1 40

References

1 Perelygina L, Chen MH, Suppiah S, Adebayo A, Abernathy E, Dorsey M et al.. Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. PLoS pathogens 2019. link 2 Vauloup-Fellous C, Ursulet-Diser J, Grangeot-Keros L. Development of a rapid and convenient method for determination of rubella virus-specific immunoglobulin G avidity. Clinical and vaccine immunology : CVI 2007. link 3 Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, Olin P, Berbers G, Rebiere I et al.. The seroepidemiology of rubella in western Europe. Epidemiology and infection 2000. link 4 Cordoba P, Grutadauria SL, Cuffini C, Zapata MT. Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina. Clinical and diagnostic laboratory immunology 1997. link 5 Pedneault L, Zrein M, Robillard L, Landry F, Lacroix M, Joncas J. Comparison of novel synthetic peptide-based DETECT-RUBELLA enzyme immunoassays with Enzygnost and IMx for detection of rubella-specific immunoglobulin G. Journal of clinical microbiology 1994. link 6 Patel N, Rocks BF, Bailey MP. A silver enhanced, gold labelled, immunosorbent assay for detecting antibodies to rubella virus. Journal of clinical pathology 1991. link 7 Thomas HI, Morgan-Capner P. The avidity of specific IgM detected in primary rubella and reinfection. Epidemiology and infection 1990. link 8 Duverlie G, Roussel C, Driencourt M, Orfila J. Latex enzyme immunoassay for measuring IgG antibodies to rubella virus. Journal of clinical pathology 1990. link 9 Hobman TC, Lundstrom ML, Gillam S. Processing and intracellular transport of rubella virus structural proteins in COS cells. Virology 1990. link90385-5) 10 Field PR, Ho DW, Cunningham AL. Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays. Journal of clinical microbiology 1988. link 11 Thomas HI, Morgan-Capner P. Specific IgG subclass antibody in rubella virus infections. Epidemiology and infection 1988. link 12 Fayram SL, Akin S, Aarnaes SL, Peterson EM, de la Maza LM. Determination of immune status in patients with low antibody titers for rubella virus. Journal of clinical microbiology 1987. link 13 Skendzel LP, Edson DC. Latex agglutination test for rubella antibodies: report based on data from the College of American Pathologists surveys, 1983 to 1985. Journal of clinical microbiology 1986. link 14 Chernesky MA, DeLong DJ, Mahony JB, Castriciano S. Differences in antibody responses with rapid agglutination tests for the detection of rubella antibodies. Journal of clinical microbiology 1986. link 15 Wittenburg RA, Roberts MA, Elliott LB, Little LM. Comparative evaluation of commercial rubella virus antibody kits. Journal of clinical microbiology 1985. link 16 Boteler WL, Barnes KJ, Buimovici-Klein E, O'Beirne AJ. Multicenter evaluation of a 1-h enzyme-linked immunosorbent assay for rubella serology. Journal of clinical microbiology 1984. link 17 Cremer NE, Hagens SJ, Fukuchi R. Improved serological diagnosis of rubella. Journal of clinical microbiology 1983. link 18 Truant AL, Barksdale BL, Huber TW, Elliott LB. Comparison of an enzyme-linked immunosorbent assay with indirect hemagglutination and hemagglutination inhibition for determination of rubella virus antibody: evaluation of immune status with commercial reagents in a clinical laboratory. Journal of clinical microbiology 1983. link 19 Meegan JM, Evans BK, Horstmann DM. Comparison of the latex agglutination test with the hemagglutination inhibition test, enzyme-linked immunosorbent assay, and neutralization test for detection of antibodies to rubella virus. Journal of clinical microbiology 1982. link 20 Lim YS, Lam CC, Lam SK. Enzyme-linked immunosorbent assay for the diagnosis of recent rubella infection. Journal of clinical pathology 1982. link 21 Schmidt NJ, Ho HH, Chin J. Application of immunoperoxidase staining to more rapid detection and identification of rubella virus isolates. Journal of clinical microbiology 1981. link 22 van Loon AM, van der Logt JT, van der Veen J. Enzyme-linked immunosorbent assay for measurement of antibody against cytomegalovirus and rubella virus in a single serum dilution. Journal of clinical pathology 1981. link 23 Brody JP, Binkley JH, Harding SA. Evaluation and comparison of two assays for detection of immunity to rubella infection. Journal of clinical microbiology 1979. link 24 Khorrami SM, Mokhtari-Azad T, Yavarian J, Nasab GS, Naseri M, Jandaghi NZ. The etiology of Rubella IgM positivity in patients with rubella-like illness in Iran from 2011 to 2013. Journal of medical virology 2015. link 25 Tipples GA, Hamkar R, Mohktari-Azad T, Gray M, Ball J, Head C et al.. Evaluation of rubella IgM enzyme immunoassays. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2004. link 26 Mrázová M, Smelhausová M, Sestáková Z, Svandová E, Benes C. The 2001 serological survey in the Czech Republic--rubella. Central European journal of public health 2003. link 27 Figueiredo CA, Oliveira MI, Curti SP, Cruz AS, Moreira E, Afonso AM et al.. RC-IAL cell line: sensitivity of rubella virus grow. Revista de saude publica 2000. link 28 Grutadauria S, Cordoba P, Cuffini C, Zapata M. Cell-fusion assay for the detection of rubella virus in Vero cells. Clinical and diagnostic virology 1998. link00019-1) 29 Böttiger B, Jensen IP. Maturation of rubella IgG avidity over time after acute rubella infection. Clinical and diagnostic virology 1997. link00018-4) 30 Lin DB, Chen CJ. Current seroepidemiology of rubella virus infection among female residents in Taiwan. Journal of medical virology 1993. link 31 Mauracher CA, Mitchell LA, Tingle AJ. Differential IgG avidity to rubella virus structural proteins. Journal of medical virology 1992. link 32 Thomas HI, Morgan-Capner P. Rubella-specific IgG1 avidity: a comparison of methods. Journal of virological methods 1991. link90160-2) 33 Barth MW, Oger J, Chantler JK. Interaction of rubella virus with human immune cells. I. Permissiveness of lymphocyte subpopulations. Viral immunology 1990. link 34 Cusi MG, Metelli R, Valensin PE. Immune responses to wild and vaccine rubella viruses after rubella vaccination. Archives of virology 1989. link 35 Hedman K, Rousseau SA. Measurement of avidity of specific IgG for verification of recent primary rubella. Journal of medical virology 1989. link 36 Katow S, Sugiura A, Janejai N. Single-serum diagnosis of recent rubella infection with the use of hemagglutination inhibition test and enzyme-linked immunosorbent assays. Microbiology and immunology 1989. link 37 Alicata P, Castro A, Faro S, Motta S. Lymphocytes proliferation kinetics and SCE variation after rubella vaccination. Mutation research 1988. link90057-7) 38 Varela Y, Ortega E, Gómez B. Quantitation of rubella virus by competitive enzyme immunosorbent assay. Journal of virological methods 1988. link90009-2) 39 Hedman K, Seppälä I. Recent rubella virus infection indicated by a low avidity of specific IgG. Journal of clinical immunology 1988. link 40 Cusi MG, Rossolini GM, Cellesi C, Valensin PE. Antibody response to wild rubella virus structural proteins following immunization with RA 27/3 live attenuated vaccine. Archives of virology 1988. link 41 Wielaard F, Denissen A, van der Veen L, Rutjes I. A sol-particle immunoassay for determination of anti-rubella antibodies; development and clinical validation. Journal of virological methods 1987. link90078-4) 42 Bowden DS, Pedersen JS, Toh BH, Westaway EG. Distribution by immunofluorescence of viral products and actin-containing cytoskeletal filaments in rubella virus-infected cells. Archives of virology 1987. link 43 Pruneda RC, Dover JC. A comparison of two passive agglutination procedures with enzyme-linked immunosorbent assay for rubella antibody status. American journal of clinical pathology 1986. link 44 Dorsett PH, Miller DC, Green KY, Byrd FI. Structure and function of the rubella virus proteins. Reviews of infectious diseases 1985. link 45 Johnson S, McAnerney JM, Schoub BD, Kidd AH. Laboratory monitoring of rubella. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1985. link 46 Safford JW, Abbott GG, Deimler CM. Evaluation of a rapid passive hemagglutination assay for anti-rubella antibody: comparison to hemagglutination inhibition and a vaccine challenge study. Journal of medical virology 1985. link 47 Tuokko H, Toivonen V, Salmi A. Subcellular fractions in rubella immunoassays. European journal of clinical microbiology 1984. link 48 Kasupski GJ, Lo PL, Gobin G, Leers WD. Clinical evaluation of the Ortho Rubella ELISA Test System. American journal of clinical pathology 1984. link 49 Lehtonen OP, Meurman OH. An ELISA for the estimation of high-avidity and total specific IgG and IgM antibodies to rubella virus. Journal of virological methods 1982. link90091-x) 50 Johnson RB, Jensen FC, Peter CR, Nakamura RM. IgG and IgM antibodies to rubella quantitated by enzyme immunoassay. Journal of immunoassay 1982. link 51 Vejtorp M, Leerhoy J. Rubella IgG antibody detection by ELISA using capillary blood samples collected on filter paper and in microtainer tubes. Acta pathologica et microbiologica Scandinavica. Section B, Microbiology 1981. link 52 Vejtorp M. Solid phase anti-IgM ELISA for detection of rubella specific IgM antibodies. Acta pathologica et microbiologica Scandinavica. Section B, Microbiology 1981. link 53 Buimovici-Klein E, O'Beirne AJ, Millian SJ, Cooper LZ. Low level rubella immunity detected by ELISA and specific lymphocyte transformation. Archives of virology 1980. link 54 Vesikari T. Suppression of lymphocyte PHA-responsiveness after rubella vaccination with Cendehill and RA 27/3 strains. Scandinavian journal of infectious diseases 1980. link 55 Deibel R, D'Arcangelis D, Ducharme CP, Schryver GD. Assay of rubella antibody by passive hemagglutination and by a modified indirect immunofluorescence test. Infection 1980. link 56 Garland SM, Locarnini SA, Gust ID. A solid-phase enzyme-linked immunosorbent assay (ELISA) for detection of antibody to rubella virus. Pathology 1979. link 57 Cleary TJ, Cid A, Ellis B, Malkus H, Noto T, Halbert S et al.. A direct enzyme-linked immunosorbent assay (ELISA) for detection of antibodies for rubella virus in human sera. Research communications in chemical pathology and pharmacology 1978. link 58 Skaug K, Gaarder PI. An indirect immunofluorescent antibody test for determination of Rubella virus specific IgM antibodies. Elimination of secondary IgM rheumatoid factor staining after absorption of serum IgG with Staphylococcal protein A. Acta pathologica et microbiologica Scandinavica. Section C, Immunology 1978. link 59 Gravell M, Dorsett PH, Gutenson O, Ley AC. Detection of antibody to rubella virus by enzyme-linked immunosorbent assay. The Journal of infectious diseases 1977. link 60 Bidwell DE, Bartlett A, Voller A. Enzyme immunoassays for viral diseases. The Journal of infectious diseases 1977. link

Rubella arthritis